A pivotal, Phase III trial of WT1 peptide vaccine in patients with Malignant Pleural Mesothelioma.
Phase of Trial: Phase III
Latest Information Update: 19 Sep 2016
At a glance
- Drugs Galinpepimut S (Primary)
- Indications Mesothelioma
- Focus Registrational; Therapeutic Use
- 19 Sep 2016 Planned initiation date changed from 1 Apr 2016 to 31 Dec 2017,as reported by SELLA Life Science media release.
- 19 Sep 2016 SELLAS plans to commence this trial in the second half of 2017, as reported by media release.
- 30 Nov 2015 Planned initiation date changed from 1 Jan 2016 to 1 Apr 2016, as reported by SELLA Life Science media release..